Back to top
more

Accelerate Diagnostics (AXDX)

(Delayed Data from NSDQ)

$1.81 USD

1.81
53,369

+0.06 (3.43%)

Updated Oct 18, 2024 03:59 PM ET

After-Market: $1.81 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value A Growth A Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 33% (82 out of 250)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

ConforMIS (CFMS) Gets FDA Approval for iTotal Hip System

by Zacks Equity Research

Medical technology company, ConforMIS, Inc. (CFMS) recently announced the receipt of FDA 510(k) clearance for its primary iTotal Hip replacement system.

    Quest Diagnostics Enhances Blueprint for Athletes Service

    by Zacks Equity Research

    Quest Diagnostics Inc. (DGX), a global provider of clinical lab services, recently expanded its biomarker testing service known as Blueprint for Athletes.

      Why Investors Should Buy Align Technology (ALGN) Right Now

      by Zacks Equity Research

      Align Technology, Inc. (ALGN), the designer and manufacturer of Invisalign System, has rallied 51.9% over the last six months, ahead of the S&P 500's 7.9% gain.

        Cooper Companies (COO) Hits 52-Week High on Solid Prospects

        by Zacks Equity Research

        The Cooper Companies (COO) rallied to a new 52-week high of $247.80 on Jun 22, closing a tad lower at $245.06.

          Why Hold Strategy is Apt for Thermo Fisher (TMO) Stock Now

          by Zacks Equity Research

          Thermo Fisher Scientific, Inc. (TMO) has rallied 13.5% over the past three months, ahead of the S&P 500's mere 4.3% gain.

            Here's Why Henry Schein is Worth Adding to Your Portfolio

            by Zacks Equity Research

            Over the last six months, Henry Schein Inc. (HSIC) was consistently trading ahead of the S&P 500 Index.

              Bio-Rad (BIO) Scores a Strong Buy Right Now: Here's How

              by Zacks Equity Research

              Bio-Rad Laboratories, Inc. (BIO) has rallied 12.9% over the last three months, ahead of the S&P 500's 4.3% gain.

                Why Investors Should Buy Edwards Lifesciences (EW) Right Now

                by Zacks Equity Research

                Leading CA-based medical equipment major Edwards Lifesciences Corporation (EW) is currently on a healthy growth trajectory.

                  Why Quest Diagnostics (DGX) is a Suitable Pick for Investors

                  by Zacks Equity Research

                  Madison, NJ-based Quest Diagnostics, Inc. (DGX), a provider of commercial laboratory services, has been on a growth trajectory of late.

                    Lantheus (LNTH) Scores a Strong Buy Right Now: Here's How

                    by Zacks Equity Research

                    Lantheus Holdings, Inc. (LNTH) has rallied 28.2% over the last three months, ahead of the S&P 500's 4.3% gain.

                      Baxter (BAX) Scales 52-Week High: What's Behind the Rally

                      by Zacks Equity Research

                      Baxter International Inc. (BAX) scaled a new 52-week high of $60.47 on Jun 21, closing a bit lower at $60.05.

                        GNC Holdings Continues to Gain from New GNC, Global Revenue

                        by Zacks Equity Research

                        On Jun 20 2017, we issued an updated research report on Pittsburgh, PA-based GNC Holdings, Inc. (GNC).

                          PerkinElmer (PKI) to Acquire German Firm EUROIMMUN for $1.3B

                          by Zacks Equity Research

                          PerkinElmer Inc. (PKI) recently announced that it will acquire EUROIMMUN Medical Laboratory Diagnostics AG for approximately $1.3 billion in cash.

                            PAREXEL Announces Acquisition by Pamplona Capital for $5B

                            by Zacks Equity Research

                            PAREXEL International Corporation (PRXL) recently announced that it has agreed to be acquired by Pamplona Capital Management, LLP.

                              Medtronic CRT Devices Improve Therapy Delivery, Cut Costs

                              by Zacks Equity Research

                              Medtronic plc (MDT) recently announced positive data on cardiac resynchronization therapy (CRT) devices within its Cardiac and Vascular segment.

                                Hologic (HOLX) Gets FDA Clearance for Aptima HSV 1 & 2 Test

                                by Zacks Equity Research

                                Hologic, Inc. (HOLX) recently received FDA approval for the commercial launch of the Aptima Herpes Simplex Virus (HSV) 1 & 2 molecular assay on the fully automated Panther system.

                                  Genomic Health Cancer Tests Strong, Operating Expenses a Woe

                                  by Zacks Equity Research

                                  On Jun 19, we issued an updated research report on Redwood City, CA-based Genomic Health Inc (GHDX), a global cancer research company with a focus on advanced molecular diagnostics.

                                    Walgreens-Greater Than AIDS Unite to Serve Against HIV/AIDS

                                    by Zacks Equity Research

                                    Walgreens Boots Alliance, Inc. (WBA) recently teamed up with Greater Than AIDS, a national public information response, focused on the U.S. domestic HIV/AIDS epidemic.

                                      Align Technology (ALGN) Enters the S&P 500 Index, Stock Up

                                      by Zacks Equity Research

                                      Align Technology, Inc. (ALGN), the California-based dental major has joined the coveted S&P 500 benchmark, after the market closed on Jun 16.

                                        Luminex (LMNX) Scores a Strong Buy Right Now: Here's How

                                        by Zacks Equity Research

                                        With solid growth prospects, Luminex Corporation (LMNX) carries a Zacks Rank #1 (Strong Buy) which is an attractive pick at present.

                                          ResMed (RMD) at 52-Week High: What's Driving the Stock?

                                          by Zacks Equity Research

                                          Share price of ResMed Inc. (RMD) scaled a new 52-week high of $79.22 on Jun 19, eventually closing a bit lower at $78.91.

                                            PAREXEL to Launch Connected Journey Data-Driven Services

                                            by Zacks Equity Research

                                            PAREXEL International Corporation (PRXL) recently announced the launch of its proprietary data-driven services, Connected Journey.

                                              Medtronic Posts Positive Result on Reactive ATP, Grows in AF

                                              by Zacks Equity Research

                                              Medtronic's (MDT) Reactive ATP therapy slows the progression of AF in patients who are being implanted with cardiac devices.

                                                Inogen (INGN) Scores a Strong Buy Right Now: Here's How

                                                by Zacks Equity Research

                                                Goleta, CA-based Inogen Inc. (INGN), a provider of portable oxygen concentrators (POC), is on a healthy growth trajectory of late.

                                                  Hologic Receives Extended FDA Clearance for SculpSure in US

                                                  by Zacks Equity Research

                                                  Hologic, Inc. (HOLX) declared that the company's subsidiary Cynosure has received FDA's expanded clearance for SculpSure.